InDex Pharmaceuticals has received a conditional approval for continued listing on Nasdaq First North Growth Market after the reverse merger of Flerie
June 7, 2024 - InDex Pharmaceuticals Holding AB (publ) ("InDex Pharmaceuticals" or the "Company") has today received a conditional approval from Nasdaq Stockholm ("Nasdaq") for continued listing of the Company's share on Nasdaq First North Growth Market. The Company has previously submitted an application for approval for continued listing as a part of the completion of the reverse merger of Flerie Invest AB.BackgroundOn May 20, 2024, InDex Pharmaceuticals entered into a conditional agreement to acquire all shares in Flerie Invest AB ("Flerie") (the “Transaction"). The Transaction